|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AGPAT3 |
Gene summary for AGPAT3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AGPAT3 | Gene ID | 56894 |
| Gene name | 1-acylglycerol-3-phosphate O-acyltransferase 3 | |
| Gene Alias | 1-AGPAT 3 | |
| Cytomap | 21q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | Q9NRZ7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56894 | AGPAT3 | P107T-E | Human | Esophagus | ESCC | 2.61e-03 | 1.74e-01 | 0.171 |
| 56894 | AGPAT3 | P127T-E | Human | Esophagus | ESCC | 1.56e-05 | 5.80e-02 | 0.0826 |
| 56894 | AGPAT3 | P128T-E | Human | Esophagus | ESCC | 3.98e-10 | 3.90e-01 | 0.1241 |
| 56894 | AGPAT3 | P130T-E | Human | Esophagus | ESCC | 1.07e-24 | 5.00e-01 | 0.1676 |
| 56894 | AGPAT3 | NAFLD1 | Human | Liver | NAFLD | 1.34e-02 | 4.75e-01 | -0.04 |
| 56894 | AGPAT3 | S43 | Human | Liver | Cirrhotic | 1.09e-03 | 1.92e-01 | -0.0187 |
| 56894 | AGPAT3 | HCC1_Meng | Human | Liver | HCC | 6.31e-39 | -5.57e-02 | 0.0246 |
| 56894 | AGPAT3 | HCC2_Meng | Human | Liver | HCC | 3.12e-10 | -3.15e-03 | 0.0107 |
| 56894 | AGPAT3 | HCC1 | Human | Liver | HCC | 4.11e-03 | 3.42e+00 | 0.5336 |
| 56894 | AGPAT3 | HCC2 | Human | Liver | HCC | 3.07e-19 | 3.98e+00 | 0.5341 |
| 56894 | AGPAT3 | Pt13.b | Human | Liver | HCC | 8.05e-03 | 2.05e-02 | 0.0251 |
| 56894 | AGPAT3 | S014 | Human | Liver | HCC | 5.31e-07 | 4.29e-01 | 0.2254 |
| 56894 | AGPAT3 | S015 | Human | Liver | HCC | 1.37e-06 | 4.80e-01 | 0.2375 |
| 56894 | AGPAT3 | S016 | Human | Liver | HCC | 3.44e-12 | 4.81e-01 | 0.2243 |
| 56894 | AGPAT3 | S027 | Human | Liver | HCC | 4.96e-03 | 5.88e-01 | 0.2446 |
| 56894 | AGPAT3 | S028 | Human | Liver | HCC | 1.10e-19 | 8.23e-01 | 0.2503 |
| 56894 | AGPAT3 | S029 | Human | Liver | HCC | 6.49e-20 | 8.78e-01 | 0.2581 |
| 56894 | AGPAT3 | C21 | Human | Oral cavity | OSCC | 5.22e-05 | 2.21e-01 | 0.2678 |
| 56894 | AGPAT3 | C30 | Human | Oral cavity | OSCC | 8.33e-22 | 8.90e-01 | 0.3055 |
| 56894 | AGPAT3 | C38 | Human | Oral cavity | OSCC | 7.07e-05 | 5.65e-01 | 0.172 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006650 | Colorectum | AD | glycerophospholipid metabolic process | 83/3918 | 306/18723 | 5.40e-03 | 3.55e-02 | 83 |
| GO:0006644 | Colorectum | AD | phospholipid metabolic process | 101/3918 | 383/18723 | 5.80e-03 | 3.67e-02 | 101 |
| GO:0045017 | Colorectum | AD | glycerolipid biosynthetic process | 69/3918 | 252/18723 | 8.33e-03 | 4.88e-02 | 69 |
| GO:0008654 | Colorectum | FAP | phospholipid biosynthetic process | 54/2622 | 253/18723 | 8.88e-04 | 9.08e-03 | 54 |
| GO:00066502 | Colorectum | FAP | glycerophospholipid metabolic process | 62/2622 | 306/18723 | 1.54e-03 | 1.38e-02 | 62 |
| GO:00066442 | Colorectum | FAP | phospholipid metabolic process | 74/2622 | 383/18723 | 2.24e-03 | 1.83e-02 | 74 |
| GO:0046473 | Colorectum | FAP | phosphatidic acid metabolic process | 12/2622 | 37/18723 | 3.43e-03 | 2.48e-02 | 12 |
| GO:0046474 | Colorectum | FAP | glycerophospholipid biosynthetic process | 44/2622 | 211/18723 | 3.98e-03 | 2.76e-02 | 44 |
| GO:00450172 | Colorectum | FAP | glycerolipid biosynthetic process | 50/2622 | 252/18723 | 6.32e-03 | 3.95e-02 | 50 |
| GO:00086544 | Esophagus | ESCC | phospholipid biosynthetic process | 162/8552 | 253/18723 | 2.59e-09 | 5.73e-08 | 162 |
| GO:00464744 | Esophagus | ESCC | glycerophospholipid biosynthetic process | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
| GO:00450175 | Esophagus | ESCC | glycerolipid biosynthetic process | 154/8552 | 252/18723 | 5.20e-07 | 6.96e-06 | 154 |
| GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
| GO:00066505 | Esophagus | ESCC | glycerophospholipid metabolic process | 174/8552 | 306/18723 | 4.92e-05 | 3.85e-04 | 174 |
| GO:00066541 | Esophagus | ESCC | phosphatidic acid biosynthetic process | 26/8552 | 33/18723 | 1.06e-04 | 7.43e-04 | 26 |
| GO:00464733 | Esophagus | ESCC | phosphatidic acid metabolic process | 28/8552 | 37/18723 | 2.00e-04 | 1.26e-03 | 28 |
| GO:00464864 | Esophagus | ESCC | glycerolipid metabolic process | 211/8552 | 392/18723 | 6.51e-04 | 3.46e-03 | 211 |
| GO:00463411 | Esophagus | ESCC | CDP-diacylglycerol metabolic process | 11/8552 | 14/18723 | 1.30e-02 | 4.27e-02 | 11 |
| GO:00464863 | Liver | NAFLD | glycerolipid metabolic process | 66/1882 | 392/18723 | 1.94e-05 | 5.52e-04 | 66 |
| GO:00450174 | Liver | NAFLD | glycerolipid biosynthetic process | 43/1882 | 252/18723 | 3.83e-04 | 5.73e-03 | 43 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa00561 | Colorectum | AD | Glycerolipid metabolism | 24/2092 | 63/8465 | 1.25e-02 | 4.54e-02 | 2.90e-02 | 24 |
| hsa005611 | Colorectum | AD | Glycerolipid metabolism | 24/2092 | 63/8465 | 1.25e-02 | 4.54e-02 | 2.90e-02 | 24 |
| hsa005615 | Liver | HCC | Glycerolipid metabolism | 41/4020 | 63/8465 | 3.59e-03 | 1.12e-02 | 6.22e-03 | 41 |
| hsa0056112 | Liver | HCC | Glycerolipid metabolism | 41/4020 | 63/8465 | 3.59e-03 | 1.12e-02 | 6.22e-03 | 41 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AGPAT3 | SNV | Missense_Mutation | c.845A>T | p.Asp282Val | p.D282V | Q9NRZ7 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| AGPAT3 | SNV | Missense_Mutation | rs774081698 | c.143N>A | p.Arg48His | p.R48H | Q9NRZ7 | protein_coding | deleterious(0.01) | benign(0.086) | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| AGPAT3 | SNV | Missense_Mutation | c.964C>A | p.Leu322Ile | p.L322I | Q9NRZ7 | protein_coding | tolerated(0.15) | benign(0.023) | TCGA-AO-A0J2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| AGPAT3 | SNV | Missense_Mutation | novel | c.661N>G | p.Thr221Ala | p.T221A | Q9NRZ7 | protein_coding | tolerated(0.44) | benign(0.105) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| AGPAT3 | SNV | Missense_Mutation | novel | c.397N>A | p.Gly133Ser | p.G133S | Q9NRZ7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |
| AGPAT3 | SNV | Missense_Mutation | novel | c.840N>C | p.Glu280Asp | p.E280D | Q9NRZ7 | protein_coding | deleterious(0.02) | benign(0.031) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| AGPAT3 | SNV | Missense_Mutation | novel | c.533C>T | p.Thr178Met | p.T178M | Q9NRZ7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| AGPAT3 | SNV | Missense_Mutation | c.942G>T | p.Trp314Cys | p.W314C | Q9NRZ7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| AGPAT3 | SNV | Missense_Mutation | c.1057N>T | p.Arg353Cys | p.R353C | Q9NRZ7 | protein_coding | deleterious(0) | possibly_damaging(0.856) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| AGPAT3 | SNV | Missense_Mutation | c.700N>A | p.Gly234Arg | p.G234R | Q9NRZ7 | protein_coding | tolerated(0.15) | benign(0.01) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |